Cardiac safety profile of rosiglitazone: A comprehensive meta-analysis of randomized clinical trials

International Journal of Cardiology

Volumn 143, Issue 2, 2010, Pages 135-140

  Mannucci, Edoardo ^a,b   Monami, Matteo ^a   Di Bari, Mauro ^a   Lamanna, Caterina ^a   Gori, Francesca ^a   Gensini, Gian Franco ^a   Marchionni, Niccolò ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Acute myocardial infarction; Heart failure; Meta analysis; Mortality; Rosiglitazone

Indexed keywords

INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

ADD ON THERAPY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG SAFETY; HEART ARREST; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPAIRED GLUCOSE TOLERANCE; MEDLINE; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 77954356742     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2009.01.064     Document Type: Article

References (22)

1. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
2. S. Singh, Y.K. Loke, and C.D. Furberg Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis JAMA 298 2007 1189 1195
3. G.A. Diamond, and S. Kaul Rosiglitazone and cardiovascular risk N Engl J Med 357 2007 938 939
4. J.J. Shuster, L.S. Jones, and D.A. Salmon Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death Stat Med 26 2007 4375 4385
5. E. Mannucci, M. Monami, and N. Marchionni Rosiglitazone and cardiovascular risk N Engl J Med 357 2007 938 940
6. C.J. Rosen The rosiglitazone story-lessons from an FDA Advisory Committee meeting N Engl J Med 357 2007 844 846
7. www.fda.gov 2007.
8. http://ctr.gsk.co.uk/welcome.asp 2007.
9. H.C. Gerstein, S. Yusuf, and J. Bosch Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial Lancet 368 2006 1096 1105
10. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
11. B. Hedblad, A. Zambanini, P. Nilsson, L. Janzon, and G. Berglund Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study J Intern Med 261 2007 293 305
12. M. van Doorn, M. Kemme, and M. Ouwens Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in type 2 diabetes mellitus patients and healthy volunteers Br J Clin Pharmacol 62 2006 391 402
13. C. Schindler, C. Ferrario, and C. Jatzke Characterization of vascular reactivity in dorsal hand veins after oral rosiglitazone treatment in healthy subjects Int J Clin Pharmacol Ther 46 2008 30 39
14. S. Rahman, A.A. Ismail, S.B. Ismail, N.N. Naing, and A.R. bdul Rahman Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study Eur J Clin Pharmacol 63 2007 733 741
15. J.M. Evans, L.A. Donnelly, A.M. Emslie-Smith, D.R. Alessi, and A.D. Morris Metformin and reduced risk of cancer in diabetic patients BMJ 330 2005 1304 1305
16. M. Monami, C. Luzzi, and C. Lamanna Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin Diabetes Metab Res Rev 22 2006 477 482
17. M. Monami, D. Balzi, and C. Lamanna Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality Diabetes Metab Res Rev 23 2007 479 484
18. H. Thisted, S.P. Johnsen, and J. Rungby Sulfonylureas and the risk of myocardial infarction Metabolism 55 2006 S16 S19
19. R.M. Lago, P.P. Singh, and R.W. Nesto Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials Lancet 370 2007 1129 1136
20. S.E. Kahn, S.M. Haffner, M.A. Heise ADOPT Study Group Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2006 2427 2443
21. P.D. Home, S.J. Pocock, H. Beck-Nielsen RECORD Study Group Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis N Engl J Med 357 2007 28 38
22. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150